Literature DB >> 10215134

Task force for the urgent response to the epidemics of sexually transmitted diseases in eastern Europe and central Asia.

M A Waugh1.   

Abstract

In summary, members of the TF/STD: share the common goal of reducing the STD burden and slowing the spread of HIV in the most affected and vulnerable countries in eastern Europe and central Asia. Contribute financially, technically or in-kind to the implementation of a joint strategy which aims: -- to create an enabling environment for STD prevention and control, and -- to strengthen the local capacity for STD prevention and care; engage in a continuous exchange of information, collaborative partnerships and coordination of activities at regional as well as country level through the TF/STD and in-country interagency working groups, respectively; concur with the priority areas for international support consisting of advocacy and policy, STD drugs, condoms, educational materials, training, applied research and surveillance; meet twice a year to review implementation progress and the need for additional assistance; as advocates of TF/STD, call on partners and other organizations to join in this important new initiative.

Keywords:  Acquired Immunodeficiency Syndrome--prevention and control; Asia; Developed Countries; Developing Countries; Diseases; Eastern Europe; Epidemics; Europe; Hiv Infections--prevention and control; Infections; International Agencies; Organization And Administration; Organizations; Programs; Reproductive Tract Infections; Sexually Transmitted Diseases--prevention and control; Summary Report; Un; Unaids; Viral Diseases; Who

Mesh:

Year:  1999        PMID: 10215134     DOI: 10.1258/0956462991912962

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  1 in total

1.  Syphilis as a social disease: experience from the post-communist transition period in Estonia.

Authors:  Anneli Uusküla; Jan F Nygård; Mari Kibur-Nygård
Journal:  Int J STD AIDS       Date:  2004-10       Impact factor: 1.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.